Trastuzumab containing regimens for early breast cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Moja, Lorenzo ^a   Brambilla, C ^b   Compagnoni, A ^b   Pistotti, V ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ALOPECIA; ANEMIA; ASTHENIA; BREAST CARCINOMA; CARDIOTOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVALUATION; FATIGUE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; REVIEW; SKIN PAIN; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ADVANCED CANCER; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BIOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CHILL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; COUGHING; DRUG FEVER; DRUG RESPONSE; ECG ABNORMALITY; EMBASE; FOLLOW UP; HEART ARRHYTHMIA; HEART BLOCK; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HYPERTENSION; INFECTION; MEDLINE; METASTASIS; METHODOLOGY; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PAROXYSMAL DYSPNEA; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PR INTERVAL; QT INTERVAL; QUALITY OF LIFE; RELIABILITY; SIDE EFFECT; SKIN DISEASE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS;

EID: 34548865008     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006243     Document Type: Review

References (28)

1. Apolone G, Joppi R, Bertele V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer 2005;93(5):504-9.
2. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002;287(22): 2973-82.
3. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 1996;14(3):737-44.
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 1999;17(9):2639-48.
5. Collier J. Panorama: Herceptin: Wanting the Wonder Drug. BMJ 2006;332(7537):368-.
6. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730): 1132-9.
7. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):iii-x, 1-173.
8. Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. In: The Cochrane Library Issue 2, 2006. Chichester, UK: John Wiley & Sons, Ltd., 2006.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
10. Egger M, Davey Smith G, Schneider M. Systematic reviews of observational studies. Systematic reviews in health care: meta-analysis in context. 2001:211-27.
11. U.S. Food and Drug Administration. FDA Oncology Tools Approval Summary for Trastuzumab for HERCEPTIN. http://www.accessdata.fda.gov/scripts/cder/ onctools/summary.cfm?ID=284 (accessed 9 Feb 2006).
12. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
13. Joppi R, Bertele V, Garattini S. Disappointing biotech. BMJ 2005;331(7521):895-7.
14. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42- 6.
15. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
16. Loke YK, Price D, Herxheimer A. Including adverse effects. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 6b. In: The Cochrane Library Issue 2, 2006. Chichester, UK: John Wiley & Sons, Ltd, 2006.
17. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
18. NICE. Breast cancer - trastuzumab (No. 34). http://www.nice.org.uk/page. aspx?o=29274 (accessed 9 Feb 2006).
19. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 2005;353(16):1659-72.
21. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Controlled Clinical Trials 1997;18(6):530-45.
22. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 2005;353(16):1673-84.
23. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
24. Shadish WR, Cook TD, Campbell DT. Statistical conclusion validity and internal validity. Experimental and quasi-experimental designs for generalized causal inference. Boston New York: Houghton Mifflin Company, 2002.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82.
26. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of Clinical Oncology 2005;23(31):7811-9.
27. The Lancet editorial. Herceptin and early breast cancer: a moment for caution. Lancet 2005;366(9498):1673.
28. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:37-42